Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2005;36:782-786
Published online before print March 3, 2005, doi: 10.1161/01.STR.0000157667.06542.b7
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
36/4/782    most recent
01.STR.0000157667.06542.b7v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kwon, S. U.
Right arrow Articles by Kim, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kwon, S. U.
Right arrow Articles by Kim, J. S.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ACETYLSALICYLIC ACID
Related Collections
Right arrow Secondary prevention
Right arrow Acute Cerebral Infarction
Right arrow Computerized tomography and Magnetic Resonance Imaging
Right arrow Doppler ultrasound, Transcranial Doppler etc.
Right arrow Antiplatelets

(Stroke. 2005;36:782.)
© 2005 American Heart Association, Inc.


Original Contributions

Cilostazol Prevents the Progression of the Symptomatic Intracranial Arterial Stenosis

The Multicenter Double-Blind Placebo-Controlled Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis

Sun U. Kwon, MD, PhD; Yong-Jin Cho, MD, PhD; Ja-Seong Koo, MD; Hee-Joon Bae, MD, PhD; Yong-Seok Lee, MD; Keun-Sik Hong, MD, PhD; Jun Hong Lee, MD Jong S. Kim, MD, PhD

From the Department of Neurology (S.U.K., J.S.K.), Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Korea; the Department of Neurology (Y.-J.C., K.-S.H.), Inje University, Ilsan Paik Hospital, Gyeonggido, Korea; the Department of Neurology (J.-S.K., H.-J.B.), Eulji General Hospital, Eulji University, Seoul, Korea; the Department of Neurology (Y.-S.L.), Seoul Municipal Boramae Hospital, Seoul National University, Seoul, Korea; and the Department of Neurology (J.H.L.), National Health Insurance Corporation Ilsan Hospital, Gyeonggido, Korea.

Correspondence to Dr Sun U. Kwon, Department of Neurology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Korea, 138-736. E-mail sunuck{at}amc.seoul.kr

Background and Purpose— Cilostazol, a phosphodiesterase inhibitor, has been reported to reduce restenosis rate after coronary angioplasty and stenting. This study was performed to investigate the effect of cilostazol on the progression of intracranial arterial stenosis (IAS).

Methods— We randomized 135 patients with acute symptomatic stenosis in the M1 segment of middle cerebral artery or the basilar artery to either cilostazol 200 mg per day or placebo for 6 months. Aspirin 100 mg per day was also given to all patients. Patients with potential embolic sources in the heart or extracranial arteries were excluded. IAS was assessed by magnetic resonance angiogram (MRA) and transcranial Doppler (TCD) at the time of recruitment and 6 months later. The primary outcome was the progression of symptomatic IAS on MRA and secondary outcomes were clinical events and progression on TCD.

Results— Thirty-eight patients were prematurely terminated. Dropout rates and reasons for dropouts were similar between the cilostazol and placebo groups. There was no stroke recurrence in either cilostazol or placebo group, but there was 1 death and 2 coronary events in each group. In cilostazol group, 3 (6.7%) of 45 symptomatic IAS progressed and 11 (24.4%) regressed. In placebo group, 15 (28.8%) of symptomatic IAS progressed and 8 (15.4%) regressed. Progression of symptomatic IAS in cilostazol group was significantly lower than that in placebo group (P=0.008)

Conclusion— Our study suggests that symptomatic IAS is a dynamic lesion and cilostazol may prevent its progression.


Key Words: atherosclerosis • cerebrovascular disorders • magnetic resonance angiography




This article has been cited by other articles:


Home page
StrokeHome page
T. N. Turan, C. P. Derdeyn, D. Fiorella, and M. I. Chimowitz
Treatment of Atherosclerotic Intracranial Arterial Stenosis
Stroke, June 1, 2009; 40(6): 2257 - 2261.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
Y. Hattori, K. Suzuki, A. Tomizawa, N. Hirama, T. Okayasu, S. Hattori, H. Satoh, K. Akimoto, and K. Kasai
Cilostazol inhibits cytokine-induced nuclear factor-{kappa}B activation via AMP-activated protein kinase activation in vascular endothelial cells
Cardiovasc Res, January 1, 2009; 81(1): 133 - 139.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
P. B. Gorelick, K. S. Wong, H.-J. Bae, and D. K. Pandey
Large Artery Intracranial Occlusive Disease: A Large Worldwide Burden but a Relatively Neglected Frontier
Stroke, August 1, 2008; 39(8): 2396 - 2399.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
H. Ishii, Y. Kumada, T. Toriyama, T. Aoyama, H. Takahashi, S. Yamada, Y. Yasuda, Y. Yuzawa, S. Maruyama, S. Matsuo, et al.
Cilostazol Improves Long-Term Patency after Percutaneous Transluminal Angioplasty in Hemodialysis Patients with Peripheral Artery Disease
Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1034 - 1040.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
C.G. Choi, D.H. Lee, J.H. Lee, H.W. Pyun, D.W. Kang, S.U. Kwon, J.K. Kim, S.J. Kim, and D.C. Suh
Detection of Intracranial Atherosclerotic Steno-Occlusive Disease with 3D Time-of-Flight Magnetic Resonance Angiography with Sensitivity Encoding at 3T
AJNR Am. J. Neuroradiol., March 1, 2007; 28(3): 439 - 446.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
J.C. Wojak, D.C. Dunlap, K.R. Hargrave, L.A. DeAlvare, H.S. Culbertson, and J.J. Connors III
Intracranial angioplasty and stenting: long-term results from a single center.
AJNR Am. J. Neuroradiol., October 1, 2006; 27(9): 1882 - 1892.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
D. K. Lee, J. S. Kim, S. U. Kwon, S.-H. Yoo, and D.-W. Kang
Lesion Patterns and Stroke Mechanism in Atherosclerotic Middle Cerebral Artery Disease: Early Diffusion-Weighted Imaging Study
Stroke, December 1, 2005; 36(12): 2583 - 2588.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
N. Nighoghossian, L. Derex, and P. Douek
The Vulnerable Carotid Artery Plaque: Current Imaging Methods and New Perspectives
Stroke, December 1, 2005; 36(12): 2764 - 2772.
[Abstract] [Full Text] [PDF]


Home page
JWatch NeurologyHome page
A New Treatment for Symptomatic Intracranial Atherosclerotic Disease?
Journal Watch Neurology, August 25, 2005; 2005(825): 1 - 1.
[Full Text]